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Abstract 
Background: Psychoses, especially schizophrenia, are often preceded by 
cognitive deficits and psychosis risk states. Altered metabolic profiles have been 
found in schizophrenia.  However, the associations between metabolic profiles 
and poorer cognitive performance and psychosis risk in the population remain to 
be determined. 
 
Methods: Detailed molecular profiles were measured for up to 8,976 individuals 
from two general population-based prospective birth cohorts: the Northern 
Finland Birth Cohort 1986 (NFBC 1986) and the Avon Longitudinal Study of 
Parents and Children (ALSPAC). A high-throughput NMR spectroscopy platform 
was used to quantify 70 metabolic measures at age 15-16 years in the NFBC 
1986 and at ages 15 and 17 years in ALSPAC.  Psychosis risk was assessed using 
the PROD-screen questionnaire at age 15-16 years in the NFBC 1986 or the 
PLIKS assessment at age 17 in ALSPAC. Cognitive measures included academic 
performance at 16 years in both cohorts and general intelligence and executive 
function in ALSPAC. Logistic regression measured cross-sectional and 
longitudinal associations between metabolic measures and psychosis risk and 
cognitive performance, controlling for important covariates.  
 
Results: Seven metabolic measures, primarily fatty acid measures, showed 
cross-sectional associations with general cognitive performance, four across 
both cohorts (LDL diameter, MUFA ratio, omega-3 ratio and DHA ratio), even 
after controlling for important mental and physical health covariates. Psychosis 
risk showed minimal metabolic associations. 
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Conclusions: Fatty acid ratios may be important in marking risk for cognitive 
deficits in adolescence. Further research is needed to clarify whether these 
biomarkers could be causal and thereby possible targets for intervention. 
 
Keywords: psychosis risk, cognition, metabolomics, lipoprotein lipids, fatty 
acids, NFBC 1986, ALSPAC  
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Introduction 
 
Brain structure and function develop rapidly during adolescence. Problems with 
this development may be evident in cognitive performance problems or in 
psychiatric symptoms in response to increasing challenges in the adolescent 
environment. Psychoses, especially schizophrenia and psychotic disorders are 
conceptualised as neurodevelopmental disorders (Murray & Lewis 1988), the 
result of a series of insults in healthy brain development. In this 
neurodevelopmental process, the adolescent period plays an important role 
(Rapoport et al. 2005; Paus et al. 2008). Risk for psychosis is increasingly being 
measured at this age, both in clinical samples (Fusar-Poli et al. 2013) and at a 
general population level (Kelleher et al. 2012). The static and dynamic cognitive 
deficits that are known to precede schizophrenia, such as deficits in general 
intelligence and specific cognitive domains, have also increasingly been 
considered (Reichenberg et al. 2010), both as markers of risk for later illness and 
as independent predictors of functioning in young adults with mental disorders 
(Fett et al. 2011; McIntyre et al. 2013; Holshausen et al. 2014) and at risk states 
for mental disorders (Carrión et al. 2013). Better understanding of the biological 
signature of brain development and of relative problems in brain development 
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has the potential to improve public mental health and individual functional 
outcomes.  
 
Metabolomics approaches utilising nuclear magnetic resonance (NMR) 
spectroscopy have shown increasing promise in characterising the molecular 
signature of body fluids for disease risk (Ala-Korpela 2007a, 2007b). NMR 
spectroscopy has particularly suited study of the molecular signature of disease 
and event risk in larger epidemiological samples. The approach has uncovered 
metabolic associations with: disease risk states, such as obesity (Würtz et al. 
2014) and insulin resistance (Würtz et al. 2012); illnesses and illness events, 
such as diabetes (Wang et al. 2015), cardiovascular events (Würtz et al. 2015), 
and all-cause mortality (Fischer et al. 2014); and health-related behaviours, such 
as alcohol consumption (Würtz et al. 2016) and physical activity (Kujala et al. 
2013). 
 
In the study of brain development and disorders, NMR spectroscopy approaches 
have identified patterns regarding schizophrenia (Holmes et al. 2006) and mild 
cognitive impairment in older people (Tukiainen et al. 2008), and have suggested 
possible molecular associations with cognitive reaction times in young people 
with schizophrenia (Scoriels et al. 2015). Mass spectrometry metabolomics 
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approaches have also shown promise in mapping molecular features of 
schizophrenia (Orešič et al. 2011; He et al. 2012; Yang et al. 2013) and of 
cognitive impairment in older people (Trushina et al. 2013; Mapstone et al. 
2014).  
 
Difficulties in adolescent cognitive performance and psychosis risk are 
associated with negative outcomes in adulthood. To our knowledge, 
metabolomics approaches have not been utilised to examine these adolescent 
characteristics at a general population level. Characterisation of the metabolic 
measures associated with relatively poorer cognition and psychosis risk in 
adolescence has the potential to improve understanding of their development.  
The present study examines if there are cross-sectional and longitudinal 
associations between a panel of metabolic measures and broad cognitive ability 
and psychosis risk in late adolescence.  
  
 9 
Methods 
 
Study populations 
 
Serum metabolic profiles were quantified from two independent general 
population-based birth cohorts: the Northern Finland Birth Cohort 1986 (NFBC 
1986) and the Avon Longitudinal Study of Parents and Children (ALSPAC) from 
the United Kingdom (UK).  
 
The NFBC 1986 is a longitudinal birth cohort, covering 99% of births in the two 
northernmost provinces of Finland, Oulu and Lapland, who had an expected 
delivery date between July 1st 1985 and June 30th 1986, details of which have 
been described elsewhere (Järvelin et al. 1993; http://kelo.oulu.fi/NFBC/). In 
brief, the cohort consisted of 9,432 live-born children, of whom 6,985 (76%) 
completed questionnaires (Miettunen et al. 2008; Taanila et al. 2009; 
Koivukangas et al. 2010; Mäki et al. 2014; Metcalf et al. 2017) and 5,606 (59%) 
provided serum samples for NMR metabolomics analysis at age 15-16 years. The 
study received ethics approval from the ethics committees of the Northern 
Ostrobothnia Hospital District and the University of Oulu and all participants and 
their parents provided written informed consent.  
 
ALSPAC is a longitudinal birth cohort, consisting of 72% of eligible expectant 
mothers in Bristol, UK, and surrounding areas, who had an expected delivery 
date between April 1st 1991 and December 31st 1992, details of which have been 
described elsewhere (Golding et al. 2001; Boyd et al. 2013; 
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http://www.bristol.ac.uk/alspac/). In brief, this consisted of 14,062 live-born 
children. Of these, 9,985 were invited to follow-up at age 15 years and 5,253 
attended (and 3,366 provided plasma samples for NMR-based metabolomics). A 
further 10,101 were invited to follow-up at age 17 years (including 782 not in 
the original sample), of whom 5,217 attended (and 3,176 provided plasma 
samples for NMR-based metabolomics). Please note that the study website 
contains details of all the data that is available through a fully searchable data 
dictionary (http://www.bris.ac.uk/alspac/researchers/data-access/data-
dictionary/). Ethical approval for the study was obtained from the ALSPAC Law 
and Ethics Committee and the Local Research Ethics Committees, and all 
participants and their parents provided written informed consent. 
 
Molecular profiling 
 
NMR spectroscopy allows for the application of metabolomics approaches in 
large-scale epidemiological samples (Soininen et al. 2015) and has been 
extensively used in multiple large-scale epidemiological studies (Mahendran et 
al. 2013; Auro et al. 2014; Fischer et al. 2014; Würtz et al. 2015; Würtz et al. 
2016). The precise methodology is described elsewhere (Soininen et al. 2009, 
2015). In brief, the NFBC 1986 participants provided serum samples at age 16 
years, while ALSPAC participants provided EDTA plasma samples at ages 15 and 
17 years and these were stored at -80C for subsequent biomarker profiling. A 
high-throughput NMR spectroscopy metabolomics platform was used for the 
quantification of 70 metabolic measures (Soininen et al. 2015), representing a 
broad molecular signature of systemic metabolism, including lipoprotein lipids 
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and subclasses, lipoprotein size, fatty acids, ratios of fatty acid subclasses to total 
fatty acids, amino acids, gluconeogenesis- and glycolysis-related metabolites, 
ketone bodies and others. All measurements were performed at the NMR 
Metabolomics Laboratory at the University of Eastern Finland, Kuopio, Finland. 
Uniform sample preparation protocols and NMR instrumentation and parameter 
were used. Details have been described elsewhere (Soininen et al. 2009; Inouye 
et al. 2010). The NFBC 1986 and ALSPAC samples were measured separately 
using identically calibrated instrumentation, though it is notable that NMR-based 
metabolic quantifications are stable over long periods (Kettunen et al. 2016). 
Standardised protocols were used to minimise any issues around sample 
transport and sample age. 
 
Academic performance 
 
Our outcomes of interest were cognitive measures and psychosis risk across the 
two samples. Our main cognitive measure was academic performance, measured 
in both samples at age 16 years. In the NFBC 1986 information on academic 
performance was provided by the National Application Register for Upper 
Secondary Education, Finland, based on nationally comparable grades of the 
final assessment of basic education. They describe the level of performance in 
relation to the objectives of basic education at the end of grade 9 (age 16). In 
ALSPAC the data on academic performance provided by the United Kingdom 
Department of Education, where performance was measured using the overall 
points score derived from the General Certificate in Secondary Education (GCSE) 
or equivalent exam. As we were interested in predictors of poorer performance, 
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in both samples the results were categorised to compare those with performance 
>1 standard deviation below the mean with the remaining group with better 
performance.  
 
Cognition 
 
Participants in the ALSPAC study performed additional cognitive tests at age 15 
and 17 years. The Wechsler Abbreviated Scale of Intelligence (WASI) was 
performed at age 15 years, at the same time as the measurement of metabolic 
measures. The N-back and Probability Reversal (PR) tests were performed at age 
17 years, 2 years after measurement of metabolic measures. The WASI is a valid 
brief measure of general intelligence in children as well as adults (Saklofske et al. 
2000; Abu-Hilal et al. 2011). The N-back and Probability Reversal each measure 
components of executive function. The N-back task is a measure of working 
memory (Miller et al. 2009). We utilised target identification accuracy on the 2-
back task for this test. Probability Reversal is a test of ability to adapt to specific 
contingencies. We utilised latency in stage 2 for this test, which was log-
transformed for normality. 
 
Psychosis risk 
 
Psychosis risk in adolescence were measured at age 16 years using the PROD-
screen questionnaire (Heinimaa et al. 2003) in the NFBC 1986 (Hurtig et al. 
2011; Therman et al. 2011; Mäki et al. 2014). This screening questionnaire 
includes twenty-one questions measuring lower level psychosis risk. Full-
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information item factor analysis has identified a three-dimensional (positive, 
negative and general) factor structure to the PROD-screen (Therman et al. 2011). 
Based on these dimensions, we classified individuals as having psychosis risk 
where they endorsed six or more out of a total of eleven positive items 
(412/6,041, 6%). This cut-off was utilised based on meta-analysis suggesting 
that the prevalence of psychotic experiences at age 16 is about 7.5% (Kelleher et 
al. 2012). 
 
Psychosis risk among ALSPAC participants was measured using clinical 
interview for psychotic-like experiences (“PLIKS”) clinical interview at age 17 
years, which was conducted by trained psychology graduates. Three main 
domains of positive psychotic symptoms were elicited: hallucinations, delusions, 
and thought interference. Interviewers rated psychosis risk as absent, suspected 
or definitely psychotic. We classified individuals as having psychosis risk where 
they showed one or more definite symptoms on interview (Zammit et al. 2009). 
Based on these criteria, we classified 232/4,480 (5%) as having psychosis risk in 
this sample. 
 
Confounding variables 
 
We considered three main potential confounders to any association between the 
metabolic measures and cognitive performance/psychosis risk: sex, 
socioeconomic status and body mass index. Sex is associated with academic 
performance and also with levels of various metabolic measures (Serbin et al. 
1990; Ishikawa et al. 2014). Socioeconomic status is associated with academic 
 14 
performance and with lifestyle factors (e.g. diet) likely to influence metabolic 
measures (Coe et al. 2013). The socioeconomic status of adolescents in the NFBC 
1986 was controlled for using the variable “maternal education”. At birth, 
mothers were asked about their own level of education attainment and this was 
classified into four groups: (1) up to 8 years of primary education; (2) 9-10 years 
of primary education; (3) vocational school or college for at least 6 months and; 
(4) commenced university education. Socioeconomic status was controlled for 
using the social class of the mother based on occupation in the ALSPAC sample. 
This included 6 groups: professional, managerial and technical, skilled non-
manual, skilled manual, partly skilled, and unskilled. Both socioeconomic 
variables were treated as linear for the purposes of analyses. Body mass index 
(BMI) was calculated from height and weight, which were measured during 
clinical examination in adolescence for both samples. The standard formula for 
BMI was used (weight(kg)/height(m)2).  
 
In addition to controlling for these factors across both cohorts, it was possible to 
control for additional mental health factors (anxiety and depression, psychosis 
risk) and physical health factors (visits to a doctor in the past six months, 
physical exercise, healthy diet) in the NFBC sample. Anxiety and depression were 
measured at age 16 years using sixteen questions from the Youth Self Report 
(Song et al. 1994). Psychosis risk was assessed as outlined above, using the 
PROD-screen (Heinimaa et al. 2003). Adolescents were asked at age 16 years 
about their physical health, physical exercise and diet. Number of visits to the 
doctor in the previous 6 months was used as a proxy for physical health, 
comparing those with 2 or more visits with those with 0-1 visits. Those who 
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described lower levels of physical activity were compared with those with higher 
levels of physical activity, comparing 0-1 hour per week of brisk physical activity 
with >1 hour per week, excluding physical activity during school hours (Koponen 
et al. 2008). Diet was considered healthy or unhealthy, depending on the amount 
of fruits, vegetables and berries used (with healthy considered as any of these on 
three or more days per week) (Koponen et al. 2008). 
 
Statistics 
 
Cognitive measures were transformed into binary outcomes for ease of 
interpretation, comparing individuals more than 1 standard deviation (SD) 
below the mean scores to the remainder of the sample. Psychosis risk status was 
a binary outcome, as described above. Metabolic measures with skewed 
distribution were normalised by log-transformation prior to analyses and all 
metabolic measures were z-transformed to examine the effect of each 1 standard 
deviation increase on the odds for the cognitive outcome. The metabolic 
measures were therefore transformed into ordinal measures for interpretation 
but they were treated as continuous for the purpose of analysis. Due to the 
correlated nature of the data, principal component analysis was used to evaluate 
the appropriate number of independent tests to correct for multiple testing. In 
this case, 90% of the variance in the 70 measures was explained by at most 12 
principal components in each cohort. Multiple testing correction therefore 
accounted for 12 independent tests using the Bonferroni method, resulting in a 
corrected P-value of <0.004. 
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Our primary hypotheses were that cognitive difficulties and psychosis risk status 
(the outcomes of interest) were associated with differences in metabolic 
measures (the main exposure of interest), both cross-sectionally and 
longitudinally. The temporal relationship between exposures and outcomes and 
the cross-sectional and longitudinal associations under review are presented in 
figure 1. For the cross-sectional analyses, a logistic regression model was fitted 
for each outcome measure (academic performance at age 16 years in the NFBC 
1986, psychosis risk at age 16 in the NFBC 1986, WASI performance at age 15 for 
ALSPAC, executive skills performance at age 17 years for ALSPAC, and psychosis 
risk at age 17 years for ALSPAC), using metabolic measures as the explanatory 
variable. Individuals with higher cognitive performance or lower psychosis risk 
were used as the reference group, so the odds ratios calculated reflect the 
association between increasing standard deviations of metabolic measures and 
poorer cognitive performance/higher psychosis risk. The two cohorts were 
analysed separately. In all analyses we initially adjusted for sex (model 1). Where 
an association was observed at the required P-value, we sequentially adjusted 
for socioeconomic status (model 2) and body mass index (model 3).  
 
Additional longitudinal analyses were performed with ALSPAC (see figure 1). In 
this case, cognitive performance and psychosis risk were also the outcomes of 
interest and metabolic measures were the explanatory variables of interest. 
Logistic regression models were fitted for each outcome (academic performance 
at age 16 years, executive function at age 17 years, psychosis risk at age 17 
years) with metabolic measures taken at age 15 years as the explanatory 
variables of interest. In these analyses we initially adjusted for sex (model 1) 
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and, where an association was observed at the required P-value, we then 
adjusted sequentially for socioeconomic status (model 2) and body mass index 
(model 3). 
 
Secondary hypotheses were tested in the cohorts separately. Our first secondary 
hypothesis was that metabolic associations with cognitive performance were not 
explained by anxiety and depression but were influenced by psychosis risk 
status. In order to test this, we compared model 3 above to a model controlling 
for depression and anxiety (model 4) in the NFBC 1986. We then compared this 
model 4 (or model 3 in the case of the ALSPAC) with a further model, controlling 
for psychosis risk (model 5). These models controlling for psychosis risk were 
then compared with a model considering interaction between psychosis risk and 
the metabolic measures. Our second secondary hypothesis was that metabolic 
associations with cognitive performance were not explained by physical health 
factors. This could only be tested in the NFBC 1986 sample, by comparing model 
3 to a model controlling for doctors visits in the previous six months, physical 
exercise and healthy diet (model 6). 
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Results 
 
The characteristics of participants in the two cohorts are given in Table 1. Higher 
academic performance in both samples was associated with female sex, with 
having mothers who were more educated or from a higher social class and with 
lower mean body mass index (more markedly in ALSPAC). In the NFBC 1986 
sample, higher academic performance was associated with higher score on 
anxiety and depression items (P<0.001), higher rates of more physical activity 
(P<0.001) and higher rates of healthy diet (P<0.001). In the ALSPAC sample, 
higher academic performance was associated with lower rates of psychosis risk 
(P<0.001). 
 
Cross-sectional associations between metabolic measures and cognitive 
performance and psychosis risk 
 
A range of apolipoprotein and fatty acid-related metabolic measures showed 
cross-sectional associations with broad cognitive performance (see figure 2). In 
the NFBC 1986 sample, 18 metabolic measures were associated with academic 
performance at age 16. These included lipids in lipoproteins, lipoprotein 
diameters, triglyceride measures and, particularly frequently, fatty acid ratios. 
Among these, LDL diameter, MUFA level, ratios of fatty acid subclasses (MUFA, 
PUFA, omega-6, omega-3, DHA, % unsaturation) to total fatty acids, citrate and 
creatinine remained associated with academic performance even after 
controlling for maternal education and body mass index (see table 2). In ALSPAC, 
nine metabolic measures were associated with general intelligence scores at age 
 19 
15 years. Among these, lipids in small HDL, LDL diameter, fatty acid levels 
(omega-3, DHA), and ratios of fatty acid subclasses (MUFA, omega-3, DHA) to 
total fatty acids were associated at P<0.004 after controlling for maternal social 
class and body mass index.  
 
There were no cross-sectional associations at P<0.004 between any of the 
metabolic measures at age 17 years and Probability Reversal at age 17 years (see 
supplementary figure 1). In the case of N-back accuracy, increasing standard 
deviations of the two DHA measures were associated with better performance. 
DHA level at age 17 years was associated in model 1 (OR=0.81, 95% CI: 0.70-
0.93, P=0.004), borderline associated in model 2 (OR=0.79, 95% CI: 0.66-0.93, 
P=0.006) and associated in model 3 (OR=0.77, 95% CI: 0.65-0.92, P=0.003). Ratio 
of DHA to total fatty acids at age 17 years was associated with N-back accuracy in 
model 1 (OR=0.78, 95% CI: 0.68-0.90, P=0.001), model 2 (OR=0.76, 95% CI: 0.64-
0.90, P=0.001), and model 3 (OR=0.76, 95% CI: 0.64-0.90, P=0.001).  
 
There was minimal evidence against the null hypothesis for cross-sectional 
associations between fatty acid levels and psychosis risk in the NFBC 1986 
sample, with none showing associations at P<0.004 (see supplementary figure 
2). In the ALSPAC sample, there were weak cross-sectional associations between 
DHA levels and psychosis risk, though these did not reach our P-value threshold 
(see supplementary figure 2). One metabolic measure, acetate, was associated 
with lower risk for psychosis (OR=0.37, 95% CI: 0.16-0.57, P<0.001). The 
evidence for this association against the null hypothesis was weaker after 
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controlling for maternal social class (OR=0.38, P=0.003) and BMI (OR=0.42, 
P=0.008). 
 
Longitudinal associations between metabolic measures and cognitive performance 
and psychosis risk 
 
The longitudinal associations between metabolic measures and cognitive 
performance are presented in figure 3. In brief, there were various associations 
between metabolic measures associated with apolipoproteins and fatty acids and 
cognitive function longitudinally. Specifically, nine measures at age 15 years 
were associated with academic performance at age 16 years (lipids in large HDL, 
LDL diameter, HDL diameter, MUFA, DHA, ratios of fatty acid subgroups to total 
fatty acids) (see table 3). Among these, four remained associated after 
controlling for maternal social class and body mass index: higher LDL diameter, 
MUFA level, ratios of MUFA and DHA to total fatty acids. Five fatty acid measures 
at age 15 years were associated with Probability Reversal latency at age 17 years 
(PUFA, omega-6, linoleic acid, omega-3 and DHA) at P<0.004 and these 
associations were broadly similar after controlling for maternal social class and 
body mass index. 
 
No metabolic measures at age 15 years were associated with N-back accuracy at 
17 years or psychosis risk at 17 years (see supplementary figure 3). 
 
The observed cross-sectional and longitudinal associations are presented 
together in table 4. 
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Metabolic measures and cognitive performance in the context of mental and 
physical health factors 
 
Cross-sectional associations between metabolic measures and cognitive 
performance, which were significant in both samples, were further tested by 
controlling for mental health factors and physical health factors. Results of these 
analyses are presented in table 5. The metabolic measures-cognitive associations 
were not attenuated in the NFBC 1986 sample after controlling for anxiety and 
depression at age 16 years. The associations were also not attenuated after 
controlling for psychosis risk, in either the NFBC 1986 or the ALSPAC. There 
were no interactions between the metabolic measures and psychosis risk in 
predicting cross-sectional cognitive outcomes for the NFBC 1986 or the ALSPAC. 
 
There was no attenuation in the association between metabolic measures and 
academic performance after controlling for physical health factors (doctors visits 
in the previous 6 months, exercise level and healthy diet) in the NFBC 1986 (see 
table 5 to compare models).  
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Discussion 
  
In this study across two general population-based cohorts, we have 
characterised the associations between metabolic measures and broad brain 
function in late adolescence. The main findings were that fatty acid metabolic 
measures and, to a lesser extent, apolipoprotein measures, were associated with 
adolescent brain function. These findings were stronger and more consistent in 
cross-sectional analyses and where academic scores and general intelligence 
were the outcomes. These findings did not appear to be related to differences in 
mental health factors or physical health factors between groups. Findings in the 
case of executive function were more nuanced, with associations between fatty 
acid measures at age 15 years and one of our two tests of executive function (PR 
latency) at age 17 years, and weaker cross-sectional associations also observed 
for omega-3 at age 15 years. Findings for psychosis risk were fewer and weaker. 
 
Metabolic measures and general intelligence 
 
While two lipoprotein metabolic measures (lipids in small HDL, LDL diameter) 
were associated with general intelligence, a range of fatty acid levels and ratios 
were associated on both cross-sectional and longitudinal analyses. The presence 
of cross-sectional and longitudinal associations across two cohorts adds weight 
to these results.  The observed associations for general intelligence are also 
meaningful in their strength. Each standard deviation increase in these fatty acid 
measures showed reduced odds of between 0.62 and 0.87 or increased odds of 
between 1.15 and 1.50 of performing more than 1 standard deviation from the 
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mean (poorest performing 15.8% of sample). While these associations are not 
large, they are meaningful.  
 
There are a number of potential explanations for the findings. Firstly, there may 
be lifestyle factors, associated with academic performance and fatty acid ratios 
that are playing a causal role. Placing these results in the context of other 
metabolomics work provides potential clues in this area. The pattern of fatty 
acids observed here has been noted in some other studies, particularly with 
regard to physical activity (Kujala et al. 2013) and cardiovascular events (Würtz 
et al. 2015), while different patterns have been observed for other outcomes (e.g. 
for alcohol consumption (Würtz et al. 2016)). It was therefore possible that 
observed associations between metabolic measures and cognition reflected a 
generally healthy metabolic profile associated with cognitive performance or the 
effects of physical activity on cognitive performance. This study suggests this 
explanation is unlikely. Controlling for three significant physical health factors 
(doctor visits, physical exercise and diet) did not significantly impact on the 
associations between the four metabolic factors most consistently associated 
with cognitive performance. In addition, controlling for significant mental health 
factors that impact on cognition, anxiety and depression and psychosis risk, did 
not impact on the observed associations. 
 
Secondly, the metabolic measures may be playing a causal role in terms of 
general cognitive ability. However, the results observed regarding omega-3 
ratios provide very limited evidence in support of Bradford Hill’s criteria around 
causality (Bradford Hill 1965). These general guidelines suggest that strength, 
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consistency and specificity of associations support causality, along with 
temporality, biological gradient, plausibility, coherence, experiment and analogy. 
Specifically, we have observed a moderate strength association, consistent 
findings between studies and limited temporal associations. One plausible 
mechanism is that an effect on general cognitive performance could be mediated 
through previously identified effects of omega-3 fatty acids on attention (Bos et 
al. 2015), which could enhance general cognitive development. Thirdly, higher 
academic performance (or a factor for which academic performance is a proxy) 
may precede the metabolic findings. Further longitudinal work would be needed 
to clarify this. 
 
Fatty acid ratios showed more consistent associations with general cognitive 
performance than individual fatty acid levels in this study. This should be 
considered in light of the correlation between absolute fatty acid levels and 
lipoprotein lipids, particularly triglycerides. Fatty acid ratios are therefore more 
reflective of the individual role of these fatty acids than fatty acid levels 
themselves. The general pattern of associations was that higher ratios of 
polyunsaturated fatty acids were associated with better performance while 
higher ratios of monounsaturated fatty acids were associated with poorer 
performance. Long chain PUFAs are important in cell membrane structure and 
function. This role may be particularly important in adolescence, a time when 
psychiatric neurodevelopmental disorders associated with cognitive deficits 
(such as schizophrenia) begin to emerge. Higher ratios of MUFA and lower ratios 
of PUFA and its sub-classes may therefore be beneficial, or reflect a beneficial 
environment, in terms of adolescent neuronal membrane function. 
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Metabolic markers and executive function 
 
The findings with regard to executive function are less consistent than those for 
general intelligence. For one test (N-back), DHA levels and ratios showed cross-
sectional associations but there were no longitudinal associations. For the other 
test (Probability Reversal), there were no cross-sectional associations but fatty 
acid levels at age 15 years (PUFAs, omega-6, linoleic acid and DHA) were 
associated with performance at 17 years. Once again, fatty acid measures, 
particularly DHA, showed the most noteworthy effects. This may suggest that 
PUFA levels in mid-adolescence are particularly important in executive function. 
It is interesting that the cross-sectional findings were present in the N-back task, 
which primarily assesses working memory, while the longitudinal findings were 
present for the Probability Reversal task, which assesses learning following a 
rule change. This aspect of executive function is evolving rapidly during 
adolescence (Blakemore & Choudhury 2006) and this may partly explain the 
differences in longitudinal and cross-sectional findings between the tests. 
However, given the variability in the findings, further replication is warranted.  
 
Metabolic markers and psychosis risk 
 
While we observed one cross-sectional association between acetate and 
psychosis risk in ALSPAC, this finding was not evident in the NFBC sample or in 
ALSPAC longitudinally. Other findings were weak and not consistent between 
samples or between cross-sectional and longitudinal analyses. One possible 
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reason for differences in findings between the NFBC 1986 and ALSPAC is that the 
measures used were quite different. The PROD-screen is a screening 
questionnaire and has limited evidence of either sensitivity or specificity at the 
cutoff used here (around 6% of the NFBC 1986 sample). It is therefore likely that 
among those who scored positive, there were many without psychosis risk as 
well as those with them. The PLIKS interview was more specific for psychosis 
risk but the outcome was therefore rarer (only 5% of the ALSPAC group). Ideally 
studies would utilise the same measures to allow for potential replication. 
 
Psychosis risk did not appear to play a major role in the cognitive findings. 
Controlling for psychosis risk did not impact on cognitive findings. This may be 
due to the relatively low numbers with psychosis risk (5-6% of the samples). 
However, the findings suggest that, at a population level at least, metabolic 
measures do not influence cognition differentially according to psychosis risk. 
Further studies with enriched psychosis risk samples may be useful to consider 
this further. 
 
Future research implications 
 
We have observed cross-sectional and longitudinal associations between 
metabolic markers and cognition. Future research should examine other specific 
cognitive domains outside of executive function. Future studies could add to 
these findings by further exploring for evidence in support of causality, for 
example by considering potential biological mechanisms through experimental 
animal studies. In addition, consideration of the role of other covariates, such as 
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exercise, would be helpful, even if this is on the same causal pathway to the 
outcome.  
 
Limitations and advantages 
 
A number of limitations of this study must be acknowledged. Firstly, much of the 
data was cross-sectional, making it difficult to more closely examine the 
directions of relationships. However, longitudinal associations between fatty 
acid metabolic measures and academic performance and executive performance 
in the ALSPAC study add considerably to the cross-sectional findings. Secondly, 
we could control for only a limited number of potential confounders in the 
ALSPAC group. However, those chosen (maternal education, body mass index) at 
least partly address a wide variety of potential confounders such as diet and 
exercise levels. Furthermore, controlling for physical health, diet and exercise 
did not impact on observed associations in the case of the NFBC 1986 sample. 
Thirdly, the main outcome of interest, academic performance, has limitations. In 
addition to reflecting a variety of cognitive processes (Rohde & Thompson 2007), 
academic performance reflects self-discipline (Duckworth & Seligman 2005), sex 
and home cultural factors, including socio-economic context. This could also be 
regarded as a strength, as academic achievement reflects a variety of personality 
and cognitive processes that are important for success into adulthood. In 
addition, this data was augmented with more specific measures of executive 
function, a key cognitive skill that advances rapidly during late adolescence. 
Fourthly, the psychosis risk outcomes had limitations, particularly in the case of 
the PROD-screen items, which has limited validity in identifying psychosis risk. 
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Fifthly, the use of body mass index in adolescence has limitations, as it is likely to 
fluctuate in adolescence in response to growth spurts. However, the use of other 
physical measures in the NFBC 1986 sample partly addresses this limitation. 
Finally, the conversion of measurements, including cognitive performance, from 
continuous into categorical will result in some loss of information. However, this 
loss of information is justified by the measures being more meaningful and 
easier to interpret. 
 
This study also has a number of important strengths. The data is derived from 
two large general population-based birth cohorts. Despite this, the findings were 
similar across the studies. Furthermore, the two samples come from different 
genetic contexts and different social contexts, including with regard to diet, 
which reduces the chances of uncontrolled confounding. As mentioned, 
information was both cross-sectional and longitudinal. We were also fortunate to 
have data on a large number of metabolic measures and sufficient participants to 
truly examine associations across two samples. Finally, we were fortunate that 
for the NFBC 1986 sample, we had rich data on physical and mental health 
factors that may have impacted on the results. 
 
Conclusion 
 
In conclusion, we have identified differences in fatty acid ratios associated with 
academic and cognitive performance in adolescence. These were strongest for 
general cognitive ability and were not explained by mental or physical health 
factors. Further analysis of these fatty acid ratios may further our understanding 
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of cognitive development at this key age, particularly in groups that are 
especially vulnerable to psychiatric co-morbidity and longer-term functional 
deficits.  
 
 
Acknowledgements: 
We are extremely grateful to all the families who took part in these studies and 
the whole NFBC 1986 and ALSPAC teams, which includes interviewers, computer 
and laboratory technicians, clerical workers, research scientists, volunteers, 
managers, receptionists and nurses. We thank professor Anna-Liisa Hartikainen 
(who launched the NFBC 1986), the NFBC project center and the University of 
Oulu. The UK Medical Research Council and Wellcome (Grant ref: 
102215/2/13/2) and the University of Bristol provide core support for ALSPAC, 
while ALSPAC metabolomics data generation was funded by the UK Medical 
Research Council (MRC – MC_UC_12013/1). This research was also supported by 
funding from the EU (QLG1-CT-2000-01643 (EUROBLCS) Grant no. E51560), 
NorFA (Grant no. 731, 20056, 30167), the NIHH (USA) 2000 (G DF682 Grant no. 
50945), and the researchers’ own funding. JM was supported by the Academy of 
Finland (Grant no. 268336). MAK was supported by the Sigrid Juselius 
Foundation, Finland. MAK and GDS work in a Unit that is supported by the 
University of Bristol and UK Medical Research Council (MC_UU_12013/1). GDS 
works in the Medical Research Council Integrative Epidemiology Unit at the 
University of Bristol (MC_UU_00011/1). This publication is the work of the 
authors and they will serve as guarantors for the contents of the paper. 
 
  
 30 
References 
 
Abu-Hilal MM, Al-Baili MA, Sartawi A, Abdel-Fattah F, & Al-Qarayout AI 
(2011). Psychometric Properties of the Wechsler Abbreviated Scale of 
Intelligence (WASI) with an Arab Sample of School Students. Individual 
Differences Research 9, 219–230. 
Ala-Korpela M (2007a). Critical evaluation of 1H NMR metabonomics of serum 
as a methodology for disease risk assessment and diagnostics. Clinical Chemistry 
and Laboratory Medicine 46, 27–42. 
Ala-Korpela M (2007b). Potential role of body fluid 1H NMR metabolomics as a 
prognostic and diagnostic tool. Expert Review of Molecular Diagnostics 7, 761–
773. 
Auro K, Joensuu A, Fischer K, Kettunen J, Salo P, Mattsson H, Niironen M, 
Kaprio J, Eriksson JG, Lehtimäki T, Raitakari O, Jula A, Tiitinen A, 
Jauhiainen M, Soininen P, Kangas AJ, Kähönen M, Havulinna AS, Ala-Korpela 
M, Salomaa V, Metspalu A, & Perola M (2014). A metabolic view on menopause 
and ageing. Nature Communications 5, 4708. 
Blakemore SJ, & Choudhury S (2006). Development of the adolescent brain: 
Implications for executive function and social cognition. Journal of Child 
Psychology and Psychiatry and Allied Disciplines 47, 296–312. 
Bos DJ, Oranje B, Veerhoek ES, Van Diepen RM, Weusten JMH, Demmelmair 
H, Koletzko B, de Sain-van der Velden MGM, Eilander A, Hoeksma M, & 
Durston S (2015). Reduced Symptoms of Inattention after Dietary Omega-3 
Fatty Acid Supplementation in Boys with and without Attention 
Deficit/Hyperactivity Disorder. Neuropsychopharmacology 40, 2298–2306. 
Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, Molloy L, 
Ness A, Ring S, & Smith GD (2013). Cohort profile: The “Children of the 90s”-
The index offspring of the avon longitudinal study of parents and children. 
International Journal of Epidemiology 42, 111–127. 
Bradford Hill A (1965). The Environment and Disease: Association or 
Causation? Proceedings of the Royal Society of Medicine 58, 295–300. 
Carrión RE, McLaughlin D, Goldberg TE, Auther AM, Olsen RH, Olvet DM, 
Correll CU, & Cornblatt BA (2013). Prediction of Functional Outcome in 
Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry 70, 1133–1142. 
Coe DP, Peterson T, Blair C, Schutten MC, & Peddie H (2013). Physical Fitness, 
Academic Achievement, and Socioeconomic Status in School-Aged Youth. Journal 
of School Health 83, 500–507. 
Duckworth AL, & Seligman MEP (2005). Self-discipline outdoes IQ in 
predicting academic performance of adolescents. Psychological Science 16, 939–
944. 
Fett AKJ, Viechtbauer W, Dominguez M de G, Penn DL, van Os J, & 
Krabbendam L (2011). The relationship between neurocognition and social 
cognition with functional outcomes in schizophrenia: A meta-analysis. 
Neuroscience and Biobehavioral Reviews 35, 573–588. 
Fischer K, Kettunen J, Würtz P, Haller T, Havulinna AS, Kangas AJ, Soininen 
P, Esko T, Tammesoo ML, Mägi R, Smit S, Palotie A, Ripatti S, Salomaa V, Ala-
Korpela M, Perola M, & Metspalu A (2014). Biomarker Profiling by Nuclear 
Magnetic Resonance Spectroscopy for the Prediction of All-Cause Mortality: An 
Observational Study of 17,345 Persons. . Public Library of Science PLoS Medicine 
 31 
11, e1001606. 
Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rössler A, 
Schultze-Lutter F, Keshavan MS, Wood S, Ruhrmann S, Seidman LJ, 
Valmaggia L, Cannon T, Velthorst E, de Haan L, Cornblatt B, Bonoldi I, 
Birchwood M, Mcglashan TH, Carpenter WT, McGorry PD, Klosterkötter J, 
McGuire P, & Yung AR (2013). The psychosis at risk state: a comprehensive 
state-of-the-art review. JAMA Psychiatry 70, 107–120. 
Golding J, Pembrey M, & Jones R (2001). ALSPAC--the Avon Longitudinal Study 
of Parents and Children. I. Study methodology. Paediatric and perinatal 
epidemiology 15, 74–87. 
He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, 
Illig T, Wang-Sattler R, & Rujescu D (2012). Schizophrenia shows a unique 
metabolomics signature in plasma. Transl Psychiatry 2, e149. 
Heinimaa M, Salokangas RK, Ristkari T, Plathin M, Huttunen J, Ilonen T, 
Suomela T, Korkeila J, & McGlashan TH (2003). PROD-screen - a screen for 
prodromal symptoms of psychosis. Int J Methods Psychiatr Res 12, 92–104. 
Holmes E, Tsang TM, Huang JTJ, Leweke FM, Koethe D, Gerth CW, Nolden 
BM, Gross S, Schreiber D, Nicholson JK, & Bahn S (2006). Metabolic profiling 
of CSF: Evidence that early intervention may impact on disease progression and 
outcome in schizophrenia. PLoS Medicine 3, 1420–1428. 
Holshausen K, Bowie CR, Mausbach BT, Patterson TL, & Harvey PD (2014). 
Neurocognition, functional capacity, and functional outcomes: The cost of 
inexperience. . Elsevier B.V. Schizophrenia Research 152, 430–434. 
Hurtig TM, Taanila A, Veijola J, Ebeling H, Mäki P, Miettunen J, Kaakinen M, 
Joukamaa M, Therman S, Heinimaa M, Järvelin MR, & Moilanen I (2011). 
Associations between psychotic-like symptoms and inattention/hyperactivity 
symptoms. Social Psychiatry and Psychiatric Epidemiology 46, 17–27. 
Inouye M, Kettunen J, Soininen P, Silander K, Ripatti S, Kumpula LS, 
Hämäläinen E, Jousilahti P, Kangas AJ, Männistö S, Savolainen MJ, Jula A, 
Leiviskä J, Palotie A, Salomaa V, Perola M, Ala-Korpela M, & Peltonen L 
(2010). Metabonomic, transcriptomic, and genomic variation of a population 
cohort. Molecular Systems Biology 6 
Ishikawa M, Maekawa K, Saito K, Senoo Y, Urata M, Murayama M, Tajima Y, 
Kumagai Y, & Saito Y (2014). Plasma and serum lipidomics of healthy white 
adults shows characteristic profiles by subjects’ gender and age. PLoS ONE 9, 1–
12. 
Järvelin MR, Hartikainen-Sorri AL, & Rantakallio P (1993). Labour induction 
policy in hospitals of different levels of specialisation. British journal of obstetrics 
and gynaecology 100, 310–315. 
Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, & Cannon M (2012). 
Prevalence of psychotic symptoms in childhood and adolescence: a systematic 
review and meta-analysis of population-based studies. Psychological Medicine 
42, 1857–63. 
Kettunen J, Demirkan A, Würtz P, Draisma HHM, Haller T, Rawal R, 
Vaarhorst A, Kangas AJ, Lyytikäinen LP, Pirinen M, Pool R, Sarin AP, 
Soininen P, Tukiainen T, Wang Q, Tiainen M, Tynkkynen T, Amin N, Zeller T, 
Beekman M, Deelen J, Van Dijk KW, Esko T, Hottenga JJ, Van Leeuwen EM, 
Lehtimäki T, Mihailov E, Rose RJ, De Craen AJM, Gieger C, Kähönen M, 
Perola M, Blankenberg S, Savolainen MJ, Verhoeven A, Viikari J, Willemsen 
 32 
G, Boomsma DI, Van Duijn CM, Eriksson J, Jula A, Järvelin MR, Kaprio J, 
Metspalu A, Raitakari O, Salomaa V, Eline Slagboom P, Waldenberger M, 
Ripatti S, & Ala-Korpela M (2016). Genome-wide study for circulating 
metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nature 
Communications 7, 1–9. 
Koivukangas J, Tammelin T, Kaakinen M, Mäki P, Moilanen I, Taanila A, & 
Veijola J (2010). Physical activity and fitness in adolescents at risk for psychosis 
within the Northern Finland 1986 Birth Cohort. Schizophrenia Research 116, 
152–158. 
Koponen H, Maki P, Halonen H, Miettunen J, Laitinen J, Tammelin T, 
Moilanen I, Taanila A, Ruokonen A, Korkeila J, & Veijola J (2008). Insulin 
resistance and lipid levels in adolescents with familial risk for psychosis. Acta 
psychiatrica Scandinavica 117, 337–341. 
Kujala UM, Makinen VP, Heinonen I, Soininen P, Kangas AJ, Leskinen TH, 
Rahkila P, Wurtz P, Kovanen V, Cheng S, Sipila S, Hirvensalo M, Telama R, 
Tammelin T, Savolainen MJ, Pouta A, O’Reilly PF, Mantyselka P, Viikari J, 
Kahonen M, Lehtimaki T, Elliott P, Vanhala MJ, Raitakari OT, Jarvelin MR, 
Kaprio J, Kainulainen H, & Ala-Korpela M (2013). Long-term leisure-time 
physical activity and serum metabolome. Circulation 127, 340–348. 
Mahendran Y, Cederberg H, Vangipurapu J, Kangas AJ, Soininen P, Kuusisto 
J, Uusitupa M, Ala-Korpela M, & Laakso M (2013). Glycerol and fatty acids in 
serum predict the development of hyperglycemia and type 2 diabetes in Finnish 
men. Diabetes Care 36, 3732–3738. 
Mäki P, Koskela S, Murray GK, Nordström T, Miettunen J, Jääskeläinen E, & 
Veijola JM (2014). Difficulty in making contact with others and social 
withdrawal as early signs of psychosis in adolescents-the Northern Finland Birth 
Cohort 1986. European Psychiatry 29, 345–351. 
Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, 
Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, 
Peltz CB, Tan MT, Kawas CH, & Federoff HJ (2014). Plasma phospholipids 
identify antecedent memory impairment in older adults. Nature medicine 20, 
415–8. 
McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, 
Kudlow P, Alsuwaidan M, & Baskaran A (2013). Cognitive deficits and 
functional outcomes in major depressive disorder: Determinants, substrates, and 
treatment interventions. Depression and Anxiety 30, 515–527. 
Metcalf SA, Jones PB, Nordstrom T, Timonen M, Mäki P, Miettunen J, 
Jääskeläinen E, Järvelin M-R, Stochl J, Murray GK, Veijola J, & Khandaker GM 
(2017). Serum C-reactive protein in adolescence and risk of schizophrenia in 
adulthood: A prospective birth cohort study. Brain, Behavior, and Immunity 59, 
253–259. 
Miettunen J, Törmänen S, Murray GK, Jones PB, Mäki P, Ebeling H, Moilanen 
I, Taanila A, Heinimaa M, Joukamaa M, & Veijola J (2008). Association of 
cannabis use with prodromal symptoms of psychosis in adolescence. The British 
journal of psychiatry : the journal of mental science 192, 470–471. 
Miller KM, Price CC, Okun MS, Montijo H, & Bowers D (2009). Is the N-back 
task a valid neuropsychological measure for assessing working memory? 
Archives of Clinical Neuropsychology 24, 711–717. 
Murray RM, & Lewis SW (1988). Is schizophrenia a neurodevelopmental 
 33 
disorder? British medical journal (Clinical research ed.) 296, 63. 
Orešič M, Tang J, Seppänen-Laakso T, Mattila I, Saarni SI, Suoma E, 
Lönnqvist J, Sysi-Aho M, Hyötyläinen T, Perälä J, & Suvisaari J (2011). 
Metabolome in schizophrenia and other psychotic disorders: a general 
population-based study. Genome medicine 3, 19. 
Paus T, Keshavan M, & Giedd JN (2008). Why do many psychiatric disorders 
emerge during adolescence? Nature Reviews Neuroscience 9, 947–957. 
Rapoport JL, Addington AM, Frangou S, & Psych MRC (2005). The 
neurodevelopmental model of schizophrenia: update 2005. Molecular psychiatry 
10, 434–449. 
Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RSE, Murray RM, 
Poulton R, & Moffitt TE (2010). Static and dynamic cognitive deficits in 
childhood preceding adult schizophrenia: A 30-year study. American Journal of 
Psychiatry 167, 160–169. 
Rohde TE, & Thompson LA (2007). Predicting academic achievement with 
cognitive ability. Intelligence 35, 83–92. 
Saklofske DH, Caravan G, & Schwartz C (2000). Concurrent Validity of the 
Wechsler Abbreviated Scale of Intelligence (WASI) with a Sample of Canadian 
Children. Canadian Journal of School Psychology 16, 87–94. 
Scoriels L, Salek RM, Goodby E, Grainger D, Dean AM, West JA, Griffin JL, 
Suckling J, Nathan PJ, Lennox BR, Murray GK, Bullmore ET, & Jones PB 
(2015). Behavioural and molecular endophenotypes in psychotic disorders 
reveal heritable abnormalities in glutamatergic neurotransmission. Translational 
Psychiatry 5, e540. 
Serbin LA, Zelkowitz P, Doyle AB, Gold D, & Wheaton B (1990). The 
socialization of sex-differentiated skills and academic performance: A 
mediational model. Sex Roles 23, 613–628. 
Soininen P, Kangas AJ, Würtz P, Suna T, & Ala-Korpela M (2015). Quantitative 
serum nuclear magnetic resonance metabolomics in cardiovascular 
epidemiology and genetics. Circulation: Cardiovascular Genetics 8, 192–206. 
Soininen P, Kangas AJ, Würtz P, Tukiainen T, Tynkkynen T, Laatikainen R, 
Järvelin M-R, Kähönen M, Lehtimäki T, Viikari J, Raitakari OT, Savolainen 
MJ, & Ala-Korpela M (2009). High-throughput serum NMR metabonomics for 
cost-effective holistic studies on systemic metabolism. Analyst 134, 1781–1785. 
Song L, Singh J, & Singer M (1994). The Youth Self-Report inventory: A study of 
its measurements fidelity. Psychological Assessment 6, 236–245. 
Taanila AM, Hurtig TM, Miettunen J, Ebeling HE, & Moilonen IK (2009). 
Association between ADHD symptoms and adolescents’ psychosocial well-being: 
a study of the Northern Finland Birth Cohort 1986. International Journal of 
Circumpolar Health 68, 133–144. 
Therman S, Heinimaa M, Miettunen J, Joukamaa M, Moilanen I, Mäki P, & 
Veijola J (2011). Symptoms associated with psychosis risk in an adolescent birth 
cohort: Improving questionnaire utility with a multidimensional approach. Early 
Intervention in Psychiatry 5, 343–348. 
Trushina E, Dutta T, Persson XMT, Mielke MM, & Petersen RC (2013). 
Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive 
Impairment and Alzheimer’s Disease Using Metabolomics. PLoS ONE 8, e63644. 
Tukiainen T, Tynkkynen T, Mäkinen V-P, Jylänki P, & Kangas A (2008). 
Biochemical and Biophysical Research Communications A multi-metabolite 
 34 
analysis of serum by 1 H NMR spectroscopy : Early systemic signs of Alzheimer’s 
disease. 375, 356–361. 
University of Oulu (2017). Northern Finland Cohorts 
Wang Q, Kangas AJ, Soininen P, Tiainen M, Tynkkynen T, Puukka K, 
Ruokonen A, Viikari J, Kähönen M, Lehtimäki T, Salomaa V, Perola M, Smith 
GD, Raitakari OT, Järvelin MR, Würtz P, Kettunen J, & Ala-Korpela M (2015). 
Sex hormone-binding globulin associations with circulating lipids and 
metabolites and the risk for type 2 diabetes: Observational and causal effect 
estimates. International Journal of Epidemiology 44, 623–637. 
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Table 1. Characteristics of the two cohorts 
 
Variable NFBC 1986 
Higher academic 
score 
 
Lower academic 
score 
ALSPAC 
Higher academic 
score 
 
Lower academic 
score 
Demographic status     
Sex     
Male 3,536 (76%) 1,110 (24%) 4,886 (81%) 1,144 (19%) 
Female 3,988 (90%) 428 (10%) 5,233 (88%) 713 (12%) 
Maternal education/social class     
Least/classes III-
M/IV/V 
1,537 (75%) 516 (25%) 1,612 (81%) 388 (19%) 
Middle/IV-NM 2,886 (82%) 647 (18%) 3,506 (89%) 448 (11%) 
Most/class I, II 2,123 (93%) 151 (7%) 2,488 (93%) 179 (7%) 
Mental health status     
Psychosis risk     
Lower risk 5,171 (87%) 785 (13%) 3,677 (95%) 184 (5%) 
Higher risk 343 (86%) 57 (14%) 175 (86%) 28 (14%) 
Depression and anxiety scores 20.127 (4.347) 19.463 (4.310) - - 
Taking medication for anxiety or 
depression 
    
No 6,073 (86%) 969 (14%) - - 
Yes 46 (84%) 9 (16%) - - 
Physical health status     
Body mass index – mean (SD) 21.1 (3.4) 21.4 (4.0) 22.8 (4.1) 24.2 (5.7) 
Visits to doctor in past 6 months     
0-1 visits 4,216 (87%) 630 (13%)   
2+ visits 1,649 (86%) 275 (14%)   
Taking insulin     
No 5,945 (86%) 931 (14%)   
Yes 24 (92%) 2 (8%)   
Physical activity     
>1 hour/week 3,913 (89%) 501 (11%)   
≤1 hour/week 2,020 (82%) 433 (18%)   
Diet     
Healthy 3,861 (91%) 375 (41%)   
Unhealthy 2,068 (79%) 543 (21%)   
NFBC 1986=Northern Finland Birth Cohort 1986; ALSPAC=Avon Longitudinal Study of Parents and Children  
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Table 2. Cross-sectional associations between metabolic measures and cognitive performance, controlling for covariates 
 
Metabolic measure NFBC 1986 (n=5,510) ALSPAC (n=3,022) 
 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
Lipids in small VLDL 1.13 (1.04, 1.22) 1.08 (0.99, 1.18) 1.08 (0.99, 1.18) - - - 
Lipids in very large HDL 0.88 (0.81, 0.95) 0.92 (0.84, 1.00) 0.92 (0.84, 1.01) - - - 
Lipids in small HDL - - - 1.21 (1.10, 1.33) 1.27 (1.14, 1.42) 1.32 (1.16, 1.50) 
LDL diameter 0.85 (0.79, 0.93) 0.87 (0.80, 0.95) 0.87 (0.80, 0.95) 0.85 (0.076, 0.95) 0.83 (0.74, 0.94) 0.78 (0.68, 0.91) 
HDL diameter 0.84 (0.78, 0.91) 0.89 (0.81, 0.97) 0.89 (0.81, 0.97) 0.85 (0.76, 0.94) 0.87 (0.77, 0.98) 0.95 (0.82, 1.09) 
Serum TG 1.14 (1.05, 1.23) 1.08 (1.00, 1.18) 1.08 (0.99, 1.18) - - - 
TG in VLDL 1.12 (1.04, 1.22) 1.07 (0.99, 1.17) 1.07 (0.98, 1.17) - - - 
TG in LDL 1.15 (1.06, 1.25) 1.12 (1.02, 1.22) 1.12 (1.02, 1.22) - - - 
PL in VLDL 1.12 (1.04, 1.21) 1.07 (0.99, 1.17) 1.07 (0.98, 1.17) - - - 
MUFAs 1.18 (1.09, 1.27) 1.15 (1.05, 1.25) 1.15 (1.05, 1.25) - - - 
Omega-3 FAs - - - 0.78 (0.70, 0.87) 0.82 (0.73, 0.94) 0.76 (0.65, 0.88) 
DHA - - - 0.71 (0.63, 0.80) 0.76 (0.66, 0.87) 0.74 (0.63, 0.87) 
MUFA/Total FA 1.24 (1.15, 1.34) 1.20 (1.11, 1.31) 1.20 (1.10, 1.31) 1.22 (1.10, 1.35) 1.23 (1.10, 1.38) 1.29 (1.13, 1.48) 
PUFA/Total FA 0.80 (0.74, 0.86) 0.83 (0.76, 0.90) 0.83 (0.76, 0.90) - - - 
Omega-6/Total FA 0.83 (0.77, 0.90) 0.87 (0.80. 0.94) 0.87 (0.80, 0.94) - - - 
LA/Total FA 0.86 (0.80, 0.93) 0.89 (0.82, 0.97) 0.89 (0.82, 0.97) - - - 
Omega-3/Total FA 0.80 (0.73, 0.87) 0.80 (0.73, 0.88) 0.80 (0.73, 0.88) 0.71 (0.64, 0.80) 0.74 (0.65, 0.84) 0.65 (0.55, 0.76) 
DHA/Total FA 0.85 (0.79, 0.93) 0.87 (0.79, 0.95) 0.86 (0.79, 0.94) 0.65 (0.58, 0.74) 0.69 (0.61, 0.79) 0.67 (0.57, 0.78) 
Unsaturated FA % 0.79 (0.73, 0.86) 0.82 (0.75, 0.89) 0.81 (0.75, 0.89) 0.85 (0.77, 0.94) 0.86 (0.77, 0.96) 0.91 (0.80, 1.04) 
Citrate 0.82 (0.76, 0.89) 0.84 (0.77, 0.92) 0.84 (0.77, 0.92) - - - 
Creatinine 0.87 (0.80, 0.95) 0.88 (0.81, 0.96) 0.88 (0.80, 0.96) - - - 
Model 1 controlled for sex; Model 2 controlled for sex and maternal education/socioeconomic status; Model 3 controlled for sex, maternal education/socioeconomic status and body mass index  
VLDL=Very Low Density Lipoprotein; HDL=High Density Lipoprotein; LDL=Low Density Lipoprotein; TG=Triglycerides; PL=Phospholip ids; FA=Fatty Acids; MUFA=Monounsaturated Fatty Acids; 
PUFA=Polyunsaturated Fatty Acids; DHA=Docosahexaenoic Acid 
Bold=P<0.004 
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Table 3. Longitudinal associations between metabolic measures and cognitive performance, controlling for covariates 
 
Metabolic measure Academic scores (n=2,893) PR latency (n=2,040) 
 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
Lipids in large HDL 0.75 (0.64, 0.89) 0.86 (0.70, 1.05) 0.77 (0.58, 1.04) - - - 
LDL diameter 0.80 (0.68, 0.93) 0.70 (0.59, 0.84) 0.62 (0.48, 0.80) - - - 
HDL diameter 0.76 (0.64, 0.89) 0.83 (0.68, 1.01) 0.74 (0.56, 0.98) - - - 
MUFA 1.23 (1.07, 1.41) 1.36 (1.16, 1.60) 1.47 (1.18, 1.83) - - - 
PUFA - - - 0.79 (0.69, 0.91) 0.75 (0.64, 0.88) 0.74 (0.63, 0.87) 
Omega-6 - - - 0.79 (0.69, 0.91) 0.77 (0.65, 0.90) 0.76 (0.65, 0.89) 
Linoleic Acid - - - 0.81 (0.70, 0.93) 0.79 (0.68, 0.92) 0.79 (0.67, 0.92) 
Omega-3 - - - 0.80 (0.70, 0.92) 0.75 (0.64, 0.89) 0.74 (0.63, 0.87) 
DHA 0.76 (0.63, 0.92) 0.91 (0.73, 1.13) 0.91 (0.68, 1.21) 0.71 (0.63, 0.80) 0.72 (0.61, 0.85) 0.72 (0.61, 0.85) 
MUFA/Total FA 1.35 (1.16, 1.56) 1.32 (1.11, 1.58) 1.50 (1.18, 1.90) - - - 
PUFA/Total FA 0.79 (0.68, 0.91) 0.77 (0.65, 0.92) 0.71 (0.56, 0.90) - - - 
Omega-3/Total FA 0.75 (0.63, 0.89) 0.84 (0.68. 1.03) 0.76 (0.57, 1.01) - - - 
DHA/Total FA 0.70 (0.58, 0.84) 0.74 (0.59, 0.93) 0.75 (0.56, 1.01) - - - 
Model 1 controlled for sex; Model 2 controlled for sex and maternal education/socioeconomic status; Model 3 controlled for se x, maternal education/socioeconomic status and body mass index 
HDL=High Density Lipoprotein; LDL=Low Density Lipoprotein; FA=Fatty Acids; MUFA=Monounsaturated Fatty Acids; PUFA=Polyunsaturated Fatt y Acids; DHA=Docosahexaenoic Acid 
Bold=P<0.004 
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Table 4. Cross-sectional associations between metabolic measures and various markers of brain function from age 15-17 years and 
longitudinal associations between metabolic measures at age 15 years and markers of brain function at age 16-17 in ALSPAC only 
 Cross-sectional Longitudinal 
Variable ALSPAC 
WASI (15) 
NFBC 
academic (16) 
NFBC psychosis 
risk (16) 
ALSPAC N-
back (17) 
ALSPAC PR 
(17) 
ALSPAC 
psychosis risk (17) 
Academic 
(16) 
N-back 
(17) 
PR (17) Psychosis 
risk (17) 
Lipoprotein subclass total lipids           
Lipids in small HDL 1.32** 1.10* 1.04 0.96 1.01 0.82 1.34* 0.99 0.92 1.03 
Lipoprotein particle size           
LDL diameter 0.78** 0.87** 0.99 1.01 1.05 1.11 0.62** 0.95 1.21* 0.98 
Fatty acids           
MUFA 1.17* 1.15** 1.09* 0.92 0.97 0.93 1.47** 0.95 0.88 1.07 
PUFA 0.98 1.00 1.07* 0.94 0.91 0.99 1.04 1.07 0.74** 1.04 
Omega-6 1.03 1.02 1.07* 0.96 0.93 1.00 1.06 1.10 0.76** 1.05 
Linoleic acid 1.02 1.03 1.07* 0.99 0.92 0.98 1.03 1.10 0.79** 1.04 
Omega-3 0.76** 0.91* 1.07* 0.82* 0.86* 0.94 0.95 0.91 0.74** 0.95 
DHA 0.74** 0.94 1.07* 0.77** 0.90 0.81 0.91 0.90 0.72** 0.93 
Fatty acid ratios           
MUFA 1.29** 1.20** 1.06 0.94 1.04 0.93 1.50** 0.93 1.14 1.06 
PUFA 0.90 0.83** 0.97 1.11 0.97 1.08 0.71* 1.23* 0.96 0.95 
Omega-3 0.65** 0.80** 1.02 0.83 0.84* 0.94 0.76 0.90 0.85* 0.90 
DHA 0.67** 0.86** 1.03 0.76 0.89 0.78* 0.75 0.88 0.79** 0.88 
HDL=High Density Lipoprotein; LDL=Low Density Lipoprotein; MUFA=Monounsaturated Fatty Acids; PUFA=Polyunsaturated Fatty Acids; DHA= Docosahexaenoic Acid 
**P<0.004; *0.004<P<0.05 
NFBC 1986=Northern Finland Birth Cohort 1986; ALSPAC=Avon Longitudinal Study of Parents and Children 
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Table 5: Cross-sectional associations between metabolic measures and academic 
performance at age 16 years, controlling for mental health factors and physical 
health factors 
Variable Model 3 
OR (95% CI) 
Model 4 (Model 
3 + anxiety and 
depression) 
OR (95% CI) 
 
Model 5 (Model 
4^ + psychosis 
risk) 
OR (95% CI) 
 
P for interaction 
(model 5 vs. 
model with 
interaction) 
 
Model 6 (Model 
3 + doctor visits, 
exercise and 
diet) OR (95% 
CI) 
NFBC sample      
LDL diameter 0.87 (0.80, 0.95) 0.83 (0.75, 0.92) 0.81 (0.73, 0.90) 0.120 0.85 (0.77, 0.94) 
MUFA/total FA 1.20 (1.10, 1.31) 1.22 (1.11, 1.35) 1.22 (1.11, 1.35) 0.502 1.23 (1.11, 1.36) 
Omega-3/total FA 0.80 (0.73, 0.88) 0.82 (0.74, 0.91) 0.83 (0.74, 0.93) 0.683 0.81 (0.73, 0.91) 
DHA/total FA 0.86 (0.79, 0.95) 0.88 (0.79, 0.97) 0.89 (0.80, 0.99) 0.918 0.87 (0.78, 0.96) 
ALSPAC sample      
LDL diameter 0.78 (0.68, 0.91) NA 0.80 (0.69, 0.93) 0.417 NA 
MUFA/total FA 1.29 (1.13, 1.48) NA 1.26 (1.10, 1.45) 0.909 NA 
Omega-3/total FA 0.65 (0.55, 0.76) NA 0.66 (0.56, 0.78) 0.300 NA 
DHA/total FA 0.67 (0.57, 0.78) NA 0.67 (0.57, 0.79) 0.496 NA 
Model 3 controlling for sex, maternal education level and body mass index 
^Model 3 in the case of the ALSPAC sample 
OR=odds ratio; 95% CI=95% confidence interval; LDL=Low Density Lipoprotein; HDL=High Density Lipoprotein; 
MUFA=Monounsaturated Fatty Acids; FA=Fatty Acids; DHA=Docosahexaenoic Acid 
 
 
Fig. 1. Overview of cross-sectional and longitudinal measurements 
 
Fig. 2. Cross-sectional associations between metabolic measures and cognitive 
performance in adolescence, controlling for sex 
 
Fig. 3. Longitudinal associations between metabolic measures and cognitive performance 
in adolescence, controlling for sex 
 
Supplementary Fig. 1. Cross-sectional associations between metabolic measures and 
executive function at age 17 years, controlling for sex 
 
Supplementary Fig. 2. Cross-sectional associations between metabolic measures and 
psychosis risk in adolescence, controlling for sex 
 
Supplementary Fig. 3. Longitudinal associations between metabolic measures at 15 years 
and executive function and psychosis risk at 17 years, controlling for sex 
